Home » Newsletters » BioWorld Science

BioWorld Science

April 11, 2018

View Archived Issues

Novartis to acquire AveXis

Promethera Biosciences raises EUR 9.3 million and acquires Baliopharm

FDA requires extended time to review additional information regarding NDA for elagolix

Mylan acquiring global marketing rights to GA Depot

Schizophrenia mouse model reveals GPR139 as key for brain habenula functioning

Prescient Therapeutics presents successful phase Ib data for PTX-200 in breast cancer

Wave Life Sciences, Deep Genomics enter oligonucleotide drug collaboration

CIS-43 antibody targets new region of circumsporozoite protein to prevent malaria infection

Initiation of phase II BELIEVE 1 study of ZYN-002 in developmental and epileptic encephalopathies

Loxo Oncology and Illumina to develop pan-cancer companion diagnostics

Novel indoleamine 2,3-dioxygenase 1 inhibitors identified at Ensemble Therapeutics

Novartis patents agents for tendon and/or ligament injuries

Data monitoring committee recommends stopping phase III ATLAS study of Inlyta due to futility

New TRPV4 antagonists discovered at GlaxoSmithKline

Merck & Co. presents novel PCSK9 inhibitors

University of Ljubljana describes novel monoamine oxidase type B inhibitors

Alexion Pharmaceuticals makes recommended public cash offer to acquire Wilson Therapeutics

Chromosome locus 16p11.2 duplication tied to higher schizophrenia risk

First patient dosed in global phase II study of tislelizumab in previously treated HCC

Afinitor Disperz receives FDA approval for the treatment of TSC-associated partial-onset seizures

Helix BioPharma receives regulatory approval to dose patients in phase II study of L-DOS47

5-HTT radiotracer [11C]DASB may predict remission after antidepressant treatment

Spectrum provides update on phase II data for poziotinib in EGFR Exon 20 mutant NSCLC

Phase III RESOLVE-IT trial reaches target recruitment for the interim analysis cohort

European Commission approves Kineret for the treatment of Still's disease

A variant in HSD17B13 gene protects from chronic liver disease development

FDA grants fast track to selinexor for the treatment of penta-refractory multiple myeloma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...